BridgeMD
New treatment option for Impulse Control Disorder
Official title rTMS Over the Dorsolateral Prefrontal Cortex for the Treatment of Impulse Control Disorders in Parkinson's Disease
ClinicalTrials.gov ID: NCT06237868
What this study is testing
- What it's testing
- This study's objective is to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (dlPFC) of patients with Parkinson's Disease (PD) who experience impulse control disorders (ICDs) on impulse control symptoms and cognitive behaviors linked to ICDs: reinforcement learning and delay-discounting. This is a randomized sham-controlled cross-over trial.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Clinician-confirmed diagnosis of PD
- Ability to provide informed consent, written and verbal
- Clinician-diagnosed impulse control disorder or impulse control behaviors including punding/hobbyism and dopamine dysregulation syndrome
- A Beck Depression Inventory (BDI) (Beck et al., 1961) score of 14 or lower
- A Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score of 20 or higher
You likely can't join if
- History of seizures or epilepsy
- History of brain lesions (such as multiple sclerosis, tumor) reported
- History of vascular issues in the brain, such as stroke
- History of a moderate to severe traumatic brain injury
- Meeting the criteria for a major psychiatric illness such as schizophrenia or depression (BDI score of 14 or higher).
- Having significant cognitive impairment (assessed by MoCA, cutoff score of 20) (Nasreddine, et al., 2005)
See the full eligibility criteria
- Clinician-confirmed diagnosis of PD
- Ability to provide informed consent, written and verbal
- Clinician-diagnosed impulse control disorder or impulse control behaviors including punding/hobbyism and dopamine dysregulation syndrome
- A Beck Depression Inventory (BDI) (Beck et al., 1961) score of 14 or lower
- A Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) score of 20 or higher
- On dopamine-replacement therapy
- History of seizures or epilepsy
- History of brain lesions (such as multiple sclerosis, tumor) reported
- History of vascular issues in the brain, such as stroke
- History of a moderate to severe traumatic brain injury
- Meeting the criteria for a major psychiatric illness such as schizophrenia or depression (BDI score of 14 or higher).
- Having significant cognitive impairment (assessed by MoCA, cutoff score of 20) (Nasreddine, et al., 2005)
- Having had TMS done in the recent past (within a year)
- Pregnancy assessed in female patients
- Intracranial metallic objects (except for dental fillings)
- Current use of substances or medications known to significantly reduce seizure threshold.
The study team makes the final eligibility decision.
Where it's taking place
- Morgantown, West Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Morgantown, West Virginia, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.